Retatrutide does not have a dose yet. It has trial arms. This page lays out every amount Lilly has tested in people, how the dose was stepped up, what each amount did, and what people using unapproved vials say they inject, along with where those online numbers come from and where they come from nowhere.
Quick answer: Retatrutide is not approved anywhere, so no label dose exists. In Lilly’s phase 3 trials adults injected it under the skin once a week, starting at 2 mg and stepping up every four weeks to a target of 4, 9 or 12 mg.[14][15] Phase 2 tested 1, 4, 8 and 12 mg for 48 weeks, with 2 mg or 4 mg starts.[1] 12 mg a week is the highest maintenance amount in the phase 2 and 3 trials reviewed. Many online protocols start lower, at 0.5 to 2 mg, and step up more slowly, and no source for those schedules was found. Trial arms are not recommendations.
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Every studied or reported retatrutide amount at a glance
One table, every source. Each row is a trial arm or a reported figure, and the last column says what kind of evidence it is. Details follow in the sections below. For the drug itself, see the retatrutide research entry.
Swipe the table sideways to see every column.
| Trial or source | Population | Route | Amount | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|
| Phase 1 single ascending dose (NCT03841630) | Healthy adults | Subcutaneous | Not consistently reported (dose levels not in the abstracts read) | Single dose | Weight effect still seen at day 43 | Published human clinical trial[4][17] |
| Phase 1b multiple ascending dose (NCT04143802) | 72 adults with type 2 diabetes | Subcutaneous | 0.5, 1.5 and 3 mg fixed; 3/6 mg and 3/6/9/12 mg stepped | Once weekly | 12 weeks | Published human clinical trial[3] |
| Phase 1, Chinese and Japanese multiple dose studies (NCT05548231, NCT04823208) | Chinese participants; Japanese adults with type 2 diabetes | Not stated | Not consistently reported | Not consistently reported | Not consistently reported | Registered human trials, completed, no results read[17] |
| Phase 2, obesity (NCT04881760) | 338 adults with obesity or overweight | Subcutaneous | 1 mg; 4 mg (start 2 or 4 mg); 8 mg (start 2 or 4 mg); 12 mg (start 2 mg) | Once weekly | 48 weeks | Published human clinical trial[1] |
| Phase 2, type 2 diabetes (NCT04867785) | 281 adults with type 2 diabetes | Subcutaneous | 0.5 mg; 4 mg (start 2 mg); 4 mg (no escalation); 8 mg (start 2 mg); 8 mg (start 4 mg); 12 mg (start 2 mg) | Once weekly | Primary endpoint 24 weeks; weight and A1C reported to 36 weeks | Published human clinical trial[2] |
| Phase 2a liver substudy | 98 participants from the phase 2 obesity trial with fatty liver | Subcutaneous | 1, 4, 8 or 12 mg | Once weekly | 48 weeks (liver fat at 24 weeks) | Published human clinical trial[5] |
| TRIUMPH-1 (NCT05929066) | 2,339 adults with obesity, no diabetes | Subcutaneous | 4, 9 or 12 mg after a 2 mg start | Once weekly, step every 4 weeks | 80 weeks; 104-week extension for 532 participants with BMI 35 or higher | Published human clinical trial[6]; extension sponsor-reported[14] |
| TRIUMPH-2 (NCT05929079) | 1,152 adults with obesity and type 2 diabetes | Subcutaneous, self-administered | 4, 9 or 12 mg after a 2 mg start | Once weekly, step every 4 weeks | 80 weeks | Published human clinical trial[7][15] |
| TRIUMPH-3 (NCT05882045) | 1,949 adults with BMI 35 or higher and established cardiovascular disease | Subcutaneous | 9 or 12 mg after a 2 mg start | Once weekly, step every 4 weeks | 80 weeks | Registered human trial, sponsor-reported topline[15][19] |
| TRIUMPH-4 (NCT05931367) | 445 adults with obesity and knee osteoarthritis | Subcutaneous | 9 or 12 mg after a 2 mg start | Once weekly, step every 4 weeks | 68 weeks | Published human clinical trial (New England Journal of Medicine, 8 November 2026); figures in this table are from the sponsor topline[13][19] |
| TRIUMPH-1-OSA and TRIUMPH-2-OSA | 243 and 448 adults with obstructive sleep apnea | Subcutaneous | 4, 9 or 12 mg | Once weekly | 80 weeks | Published human clinical trial[9] |
| TRANSCEND-T2D-1 (NCT06354660) | 537 adults with inadequately controlled type 2 diabetes | Subcutaneous | 4, 9 or 12 mg after a 2 mg start | Once weekly, step every 4 weeks | 40 weeks | Published human clinical trial[8][12] |
| TRANSCEND-T2D-2 (NCT06260722) | 1,298 adults with type 2 diabetes on metformin; open label versus semaglutide 2 mg | Subcutaneous | 9 or 12 mg after a 2 mg start | Once weekly, step every 4 weeks | 80 weeks; 24-week extension for about 650 | Registered human trial, sponsor-reported topline[16][20] |
| TRANSCEND-CKD (NCT05936151) | 146 adults with chronic kidney disease | Subcutaneous | Maximum tolerated dose up to 12 mg, or placebo | Once weekly | 24 weeks (primary endpoint) | Registered human trial; design paper only[11][18] |
| Other Lilly phase 3 and 3b trials (TRIUMPH-5, -6, -9, T2D-3, outcomes, liver, back pain) | Obesity, diabetes, kidney, heart, liver and back pain populations | Subcutaneous | Not consistently reported (registry summaries do not list milligram arms) | Once weekly | Up to 113 weeks (TRIUMPH-9) | Registered human trials, no results[21] |
| Hudson Biotech phase 2 (NCT07467447) | 300 planned adults with obesity or overweight; one site in China | Subcutaneous | Maintenance 1, 4, 8 or 12 mg, with escalation regimens | Once weekly | 48 weeks plus 4 weeks follow-up | Registered human trial, recruiting[22] |
| Lilly expanded access (NCT07629401) | Adults with BMI 35 or higher and at least two serious complications | Not stated | Not consistently reported | Not consistently reported | Not consistently reported | Expanded access record[23] |
| Forums, blogs, education and affiliate sites | People using unapproved vials | Subcutaneous injection | Starts of 0.25 to 2 mg; ongoing 1 to 8 mg a week; steps every 2 to 8 weeks | Weekly; some split into 2 or 3 injections | 8-week cycles, 12 or 24-week blocks, open-ended | Community, vendor or clinic reported (Tier 6); origin unclear[38][39][41][44][45][48] |
| Prescribing information | Not applicable | Not applicable | None exists; no regulator has approved retatrutide | Not applicable | Not applicable | Prescribing information (label): none |
Phase 2 arm labels such as “start 2 mg” follow the papers. “Step” means the weekly amount rises at the interval shown until the target is reached.
Where these figures come from
The trial numbers trace to a short list of papers, Lilly releases and registry records. The online numbers mostly do not, and that matters for how much weight to give them.
The most-reported figure is a 2 mg start with a step every 4 weeks, finishing at 4, 9 or 12 mg. It comes from the TRIUMPH and TRANSCEND programs: the design paper describes it,[10] and Lilly’s releases state the steps for TRIUMPH-1, -2, -3 and -4 and TRANSCEND-T2D-1 and -2.[12][13][14][15][16] The second most-reported set, 1, 4, 8 and 12 mg, is the phase 2 obesity design from the 2023 NEJM paper.[1] The 8 mg arm did not carry into phase 3, which used 4, 9 and 12 mg.
Human evidence exists for every trial amount above. Peer reviewed so far: phase 1b, phase 2 in obesity and in diabetes, the liver substudy, TRIUMPH-1 and -2, the two sleep apnea trials and TRANSCEND-T2D-1. TRIUMPH-3, TRIUMPH-4, TRANSCEND-T2D-2 and the TRIUMPH-1 extension exist only as company announcements. Animal evidence is two papers, neither with amounts in the abstract, so no animal figure is used here and none should be turned into a human amount.
No practitioner protocol was found, and one clinic education page states outright that no community or typical dose has been published.[49] The community figures come from forum posts, a personal blog, education sites, affiliate pages and a roundup of Reddit threads. None names an original source for its starting amounts, slower step intervals or cycle lengths.
The 0.5 mg start deserves a closer look. Real 0.5 mg arms exist, but as fixed weekly doses in the phase 1b trial and the phase 2 diabetes trial,[2][3] never as a starting step in any trial reviewed. One education page gives “the lowest Phase 2 dose” as its reason to start at 0.5 mg.[41] Treat that link as a likely mix-up, an inference and not a confirmed one.
Copying is easy to spot. The same arithmetic examples recur, such as 10 mg plus 2 mL of water making 5 mg/mL, which is division and not independent evidence. Some pages print a “phase 2 ladder” of 2, 4, 8 and 12 mg and credit the 2023 paper, yet the text read says only that escalation happened every 4 weeks for up to 12 weeks from a 2 mg or 4 mg start and gives no step list.[1] One site prints two schedules that disagree with each other, and its reference list carries identifiers that do not match the papers it names.[45]
Weight-based conversions have no support. Every trial used fixed milligram doses, covered in the FAQ below.
Detailed human data
This section works through the published trials in order, then compares them. Weight figures below carry their estimand, which is the rule for handling people who stopped the drug or took other weight-loss treatment. The treatment-regimen estimand counts everyone as randomized, whatever they did next. The efficacy estimand asks what would have happened if everyone had stayed on the drug. Efficacy numbers are always the bigger ones, and they are the numbers that reach headlines.
Phase 1: the first weekly doses
The phase 1b trial gave 72 adults with type 2 diabetes once-weekly injections for 12 weeks in five dose groups: 9 people on 0.5 mg, 9 on 1.5 mg, 11 on 3 mg, 11 on a 3 then 6 mg step, and 12 on a 3, 6, 9 then 12 mg climb. The half-life was about 6 days, which is why the drug is dosed weekly. Placebo-adjusted weight loss grew with dose, reaching up to 8.96 kg in the group that climbed to 12 mg.[3] The first-in-human single dose study is reported in the Cell Metabolism paper, which says a single dose lowered body weight for up to day 43.[4]
Phase 2 in obesity (48 weeks)
This is the only trial reviewed that tested 1 mg and 8 mg in people with obesity, and the only one that put two starting doses side by side. Participants were randomized to a fixed target and a starting dose of 2 mg or 4 mg, then stepped up every 4 weeks for up to 12 weeks.[1]
Swipe the table sideways to see every column.
| Arm (weekly) | People | Weight at 24 weeks | Weight at 48 weeks | Nausea | Stopped for side effects |
|---|---|---|---|---|---|
| Placebo | 70 | -1.6% | -2.1% | 8 (11%) | 0 |
| 1 mg | 69 | -7.2% | -8.7% | 10 (14%) | 5 (7%) |
| 4 mg, start 2 mg | 33 | -11.8% | -16.3% | 6 (18%) | 2 (6%) |
| 4 mg, start 4 mg | 34 | -13.9% | -17.8% | 12 (36%) | 3 (9%) |
| 8 mg, start 2 mg | 35 | -16.7% | -21.7% | 6 (17%) | 5 (14%) |
| 8 mg, start 4 mg | 35 | -17.9% | -23.9% | 21 (60%) | 2 (6%) |
| 12 mg, start 2 mg | 62 | -17.5% | -24.2% | 28 (45%) | 10 (16%) |
Source: full text of the 2023 paper.[1] Combined arms in the abstract: 4 mg -12.9% at 24 weeks and -17.1% at 48; 8 mg -17.3% and -22.8%. At 48 weeks, weight loss of 15% or more occurred in 60% (4 mg), 75% (8 mg) and 83% (12 mg) versus 2% on placebo. Subgroups of 33 to 35 people are too small to rank.
The start-dose effect is the clearest signal in this trial. Starting the 4 mg arm at 4 mg instead of 2 mg doubled nausea, 36% against 18%. Starting the 8 mg arm at 4 mg took nausea from 17% to 60%. The 4 mg starts gave somewhat larger early weight loss (for example -17.9% versus -16.7% at 24 weeks in the 8 mg arms), a small difference next to the nausea gap, in subgroups of 33 to 35 people. Heart rate rose with dose and peaked at 24 weeks, and 8 participants had protocol-driven dose reductions because BMI dropped.[1] In the liver substudy, relative liver fat fell by 42.9% (1 mg), 57.0% (4 mg), 81.4% (8 mg) and 82.4% (12 mg) at 24 weeks.[5]
Phase 2 in type 2 diabetes (36 weeks of results)
The diabetes trial is the only one with a 0.5 mg arm and the only one that compared slow and fast climbs to the same 8 mg target. Comparators were placebo and dulaglutide 1.5 mg.[2]
Swipe the table sideways to see every column.
| Arm (weekly) | People (safety set) | A1C change at 24 weeks | Weight change at 36 weeks |
|---|---|---|---|
| Placebo | 45 | -0.01% | -3.00% |
| Dulaglutide 1.5 mg | 46 | -1.41% | -2.02% |
| Retatrutide 0.5 mg | 47 | -0.43% | -3.19% |
| 4 mg, start 2 mg | 23 | -1.39% | -7.92% |
| 4 mg, no escalation | 24 | -1.30% | -10.37% |
| 8 mg, slow (start 2 mg) | 26 | -1.99% | -16.81% |
| 8 mg, fast (start 4 mg) | 24 | -1.88% | -16.34% |
| 12 mg, start 2 mg | 46 | -2.02% | -16.94% |
Source: published abstract.[2] The abstract does not name an estimand.
Two things stand out. The 0.5 mg arm did no better than placebo on weight (-3.19% versus -3.00%), and its A1C change was not significantly different from placebo.[2] And the fast climb to 8 mg was the arm with the most stomach and gut events, 50%, against 13% on 0.5 mg and 35% across all retatrutide arms (placebo 13%, dulaglutide 35%).[2]
Phase 3 and the later trials
Phase 3 dropped 1 mg and 8 mg, fixed the start at 2 mg and moved to 4, 9 and 12 mg targets. The table gives both estimands where both exist. Blank cells mean the source did not report that estimand.
Swipe the table sideways to see every column.
| Trial and arm | Duration | Treatment-regimen estimand | Efficacy estimand | Source |
|---|---|---|---|---|
| TRIUMPH-1, 4 mg | 80 weeks | -17.6% | -19.0% | Journal[6]; company[14] |
| TRIUMPH-1, 9 mg | 80 weeks | -23.7% | -25.9% | Journal[6]; company[14] |
| TRIUMPH-1, 12 mg | 80 weeks | -25.0% | -28.3% | Journal[6]; company[14] |
| TRIUMPH-1, placebo | 80 weeks | -3.9% | -2.2% | Journal[6]; company[14] |
| TRIUMPH-2, 4 mg (type 2 diabetes) | 80 weeks | -11.9% | -12.7% | Journal[7]; company[15] |
| TRIUMPH-2, 9 mg | 80 weeks | -16.8% | -19.1% | Journal[7]; company[15] |
| TRIUMPH-2, 12 mg | 80 weeks | -18.8% | -20.8% | Journal[7]; company[15] |
| TRIUMPH-2, placebo | 80 weeks | -5.1% | -4.0% | Journal[7]; company[15] |
| TRIUMPH-3, 9 mg (severe obesity, heart disease) | 80 weeks | -21.6% | Company[15] | |
| TRIUMPH-3, 12 mg | 80 weeks | -22.6% | Company[15] | |
| TRIUMPH-3, placebo | 80 weeks | -3.2% | Company[15] | |
| TRIUMPH-4, 9 mg (knee osteoarthritis) | 68 weeks | -20.0% | -26.4% | Company[13] |
| TRIUMPH-4, 12 mg | 68 weeks | -23.7% | -28.7% | Company[13] |
| TRIUMPH-4, placebo | 68 weeks | -4.6% | -2.1% | Company[13] |
| TRANSCEND-T2D-1, 4 mg | 40 weeks | -11.5% | -11.5% | Journal[8]; company[12] |
| TRANSCEND-T2D-1, 9 mg | 40 weeks | -13.9% | -15.5% | Journal[8]; company[12] |
| TRANSCEND-T2D-1, 12 mg | 40 weeks | -15.3% | -16.8% | Journal[8]; company[12] |
| TRANSCEND-T2D-1, placebo | 40 weeks | -2.6% | -2.5% | Journal[8]; company[12] |
| TRANSCEND-T2D-2, 9 mg (open label) | 80 weeks | -19.5% | Company[16] | |
| TRANSCEND-T2D-2, 12 mg | 80 weeks | -20.9% | Company[16] | |
| TRANSCEND-T2D-2, semaglutide 2 mg | 80 weeks | -9.4% | Company[16] |
Each trial enrolled a different population, so rows from different trials are not a head-to-head comparison. Placebo rows differ by estimand because people on placebo who started other weight-loss treatment are counted differently.
The 104-week extension of TRIUMPH-1
Lilly extended TRIUMPH-1 to 104 weeks in 532 participants with BMI 35 or higher who tolerated their dose. Participants escalated to their maximum tolerated 9 or 12 mg. The figures below come from the company release only, with the arm labels it uses.[14]
| Arm | Efficacy estimand | Treatment-regimen estimand |
|---|---|---|
| 4 mg to maximum tolerated dose | -27.9% | -25.7% |
| 9 mg to maximum tolerated dose | -29.5% | -28.7% |
| 12 mg to maximum tolerated dose | -30.3% | -29.9% |
| Placebo to maximum tolerated dose | -19.2% | -18.9% |
What the dose response shows
Weight loss climbs with dose and then flattens. In TRIUMPH-1, moving from 4 mg to 9 mg added about six points (17.6% to 23.7%), while moving from 9 mg to 12 mg added about one (to 25.0%). Phase 2 shows the same curve: 8.7% at 1 mg, 17.1% at 4 mg, 22.8% at 8 mg, 24.2% at 12 mg.[1][6] The estimand changes the picture by a visible amount:
The costs also rise with dose. In TRIUMPH-1, stopping for side effects was reported in 4.1%, 6.9% and 11.3% at 4, 9 and 12 mg against 4.9% on placebo, and weight loss of 30% or more (efficacy estimand) occurred in 15.3%, 37.9% and 45.3% against 0.5%.[14] In TRIUMPH-2, diarrhea was 27%, 34% and 34% against 13% on placebo, nausea 14%, 21% and 28% against 8%, dysesthesia (abnormal skin sensations) 4%, 6% and 7% against 1%, and low blood pressure 1%, 5% and 6% against under 1%.[7] In TRIUMPH-4, dysesthesia was 8.8% at 9 mg and 20.9% at 12 mg against 0.7%.[13] The 12 mg arm buys little extra weight loss over 9 mg and carries visibly more of these effects.
Other outcomes that vary by dose: in the sleep apnea trials the apnea-hypopnea index (breathing pauses per hour) fell by 22.9, 34.3 and 31.7 events per hour at 4, 9 and 12 mg in TRIUMPH-1-OSA against 9.9 on placebo;[9] in the TRIUMPH-1 knee osteoarthritis substudy (574 people), pain scores improved by 1.6 and 1.8 points versus placebo in the two retatrutide groups reported, under the hybrid estimand.[6] Liver fat figures are in the phase 2 section above.

Animal research amounts
Retatrutide has animal data, but the amounts are not in the abstracts read and are not translated here. Animal doses do not convert into human amounts, and no source reviewed claims otherwise. A 2026 review covers the molecule’s design and pharmaceutical development.[26]
| Research objective | Species or model | Amount studied | Frequency | Duration | Route | Source |
|---|---|---|---|---|---|---|
| Glucose control and body weight | Obese mice (preclinical work in the discovery paper) | Not consistently reported | Not consistently reported | Not consistently reported | Not consistently reported | Published animal research (Tier 3)[4] |
| Weight and metabolic outcomes with cagrilintide | Obese male rats | Not consistently reported | Not consistently reported | Not consistently reported | Not consistently reported | Published animal research (Tier 3)[25] |
Practitioner and community-reported retatrutide protocols
None of what follows is clinical evidence. These are numbers as written on forums, a personal blog, education sites and affiliate pages, grouped here because people search for them. No practitioner (clinician) protocol was found; the one clinic page located says no community dose has been published and that 5 or 10 mg weekly has not been studied.[49] Reddit threads could not be read directly, so the Reddit entries are second-hand through a roundup page.
Swipe the table sideways to see every column.
| Reported item | As reported | Source type | Source |
|---|---|---|---|
| Starting amount, forum thread (July 2026, 12 posts) | Start at 1 mg; 0.5 mg if new to GLP-1 drugs; “1 or 2 mg” | Community forum (Tier 6) | EliteFitness[38] |
| Planned ramp, same thread | 1 mg for 8 weeks, then 2 mg for 8 weeks, up to 4 mg; another user used 4-week blocks at 1, then 1.5, then 2 mg | Community forum (Tier 6) | EliteFitness[38] |
| Ongoing amounts, same thread | “1 mg a week” works; “4 mg a week is terrific”; some go to 4 or 5 mg; one user “would not push more than 5 mg” | Community forum (Tier 6) | EliteFitness[38] |
| Starting and stepping, forum thread (June 2026, 16 posts) | Original poster ran 4 mg weekly for about two weeks and had nausea. Replies: start at 2 mg then 4 mg after 3 to 4 weeks; start at 1.0 mg and add 0.5 mg every 3 to 4 weeks; start at 1 mg and add 1 mg every 2 to 3 weeks; one user never above 3 mg | Community forum (Tier 6) | Evolutionary.org[39] |
| Personal account | Start 0.5 mg, add 0.5 mg every 2 weeks, an 8-week cycle | Personal blog post (Tier 6) | Substack, Nov 2025[40] |
| Education site: start and path | Start 0.5 mg (“lowest Phase 2 dose”); path 0.5, 1, 2, 4, then 8 mg, one step every 4 weeks, or every 6 to 8 weeks if stomach symptoms occur. No sources given for the dosing | Education site, no author sources (Tier 6) | Peptidepedia[41] |
| Education wiki | Start 0.5 mg, target 8 to 12 mg, maximum 12 mg, 48-week cycle | Education site (Tier 6) | Peptide Protocol Wiki[42] |
| Education site: broad ranges | Start 0.25 to 0.5 mg; 1.5 to 4 mg over 8 to 12 weeks; “main protocol” 0.5 mg three times weekly; an 8 mg “advanced” tier; 8 weeks on and 8 off. No sources for the community figures | Education site (Tier 6) | The Peptide Catalog[44] |
| Education site: trial-style ladder | Start 2 mg and follow the phase 3 ladder, citing the 2025 TRIUMPH design paper | Education site, traceable to a trial (Tier 6 citing Tier 1 design) | Peptide Dosing Protocols[43][10] |
| Education site: “typical” range | “Typical” 2 to 8 mg; 12-week and 24-week blocks. Two schedules on the same page disagree | Education site (Tier 6); conflicting reports | PeptideDosage.org[45] |
| Affiliate planner pages | Standard 2, 4, 8, 12 mg ladder; a “slow” variant with 6-week steps | Affiliate content site (Tier 6) | GLP3 Planner[46] |
| Reddit roundup (second-hand) | Many start at 0.5 mg; a 4 to 8 mg band; steps every 6 to 8 weeks per one r/Retatrutide beginner thread; one r/Biohackers user split a 0.5 mg amount | Secondary summary of Reddit posts (Tier 6) | GLP3 Planner[47] |
| Slow ramp over 36 weeks | 0.5 mg weeks 1 to 4, 1 mg weeks 5 to 8, then 2, 3, 4, 5, 8, 10 and 12 mg, reaching 12 mg over 36 weeks. Labelled as community practice, no source | Affiliate content site (Tier 6) | Middleway Nutrition[48] |
Reading the table: starts cluster between 0.5 and 2 mg, ongoing amounts between 1 and 5 mg, steps every 2 to 8 weeks, and cycles of 8, 12, 24, 36 or 48 weeks. The trials used a 2 mg start, 4-week steps, no cycles and no stops. Between 1 mg and 4 mg weekly, the only fixed-dose human data are the phase 1b groups on 1.5 mg and 3 mg for 12 weeks (9 and 11 people) and the phase 2 1 mg arm. Weekly amounts of 5 mg and 10 mg were not maintenance arms in any trial reviewed.[1][3]
Reconstitution examples as printed on other sites
Retatrutide from unapproved sources is described online as a freeze-dried powder to be mixed with water before injecting. The examples below are only concentration arithmetic copied between sites, vial mg divided by mL of water, so repetition here is not independent confirmation of anything. The sites list vial sizes of 5, 6, 7, 10, 12, 15, 20, 24, 30, 36, 40, 48, 50 and 60 mg.[44] For the method, see the reconstitution guide, the units guide and the reconstitution calculator.
| Vial | Water added | Concentration printed | Source |
|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | [43][45] |
| 10 mg | 2 mL | 5 mg/mL | [41] |
| 10 mg | 10 mL | 1 mg/mL | [41] |
| 10 mg | 1 mL | 10 mg/mL | [48] |
| 10 mg | 4 mL | 2.5 mg/mL | [48] |
| 12 mg | 1.2 mL | 10 mg/mL | [43] |
| 20 mg | 2 mL | 10 mg/mL | [43] |
| 24 mg | 2.4 mL | 10 mg/mL | [43] |
How many weeks a vial lasts: the arithmetic
The weeks a vial covers equal vial mg divided by weekly mg. This is plain division and assumes the label is accurate. Independent testing, covered below, does not support that assumption.
| Labeled vial | 1 mg weekly | 2 mg weekly | 4 mg weekly | 8 mg weekly | 12 mg weekly |
|---|---|---|---|---|---|
| 5 mg | 5 | 2.5 | 1.25 | 0.63 | 0.42 |
| 10 mg | 10 | 5 | 2.5 | 1.25 | 0.83 |
| 20 mg | 20 | 10 | 5 | 2.5 | 1.67 |
| 30 mg | 30 | 15 | 7.5 | 3.75 | 2.5 |
Escalation, timing, duration, routes
The trials give the only documented ladder. Every phase 3 trial starts at 2 mg, then steps every 4 weeks.[10][14]
| Target | Steps | First week at target (arithmetic from 4-week steps) |
|---|---|---|
| 4 mg | 2, then 4 | Week 5 |
| 9 mg | 2, 4, 6, then 9 | Week 13 |
| 12 mg | 2, 4, 6, 9, then 12 | Week 17 |
Starting dose matters most. In phase 2, starting the 8 mg arm at 4 mg instead of 2 mg took nausea from 17% to 60%, and starting the 4 mg arm at 4 mg doubled it, 18% to 36%.[1] In the diabetes trial the fast climb to 8 mg had the most stomach and gut events, 50%.[2] That is the best-documented reason the phase 3 trials start low.
Dosing is once weekly, which fits a half-life of about 6 days in the phase 1b study.[3][37] Every trial with published methods used subcutaneous injection, and TRIUMPH-2 participants injected themselves.[7] No oral retatrutide was found; LY4086940 is a different, oral Lilly triple agonist.
Durations run 12 weeks (phase 1b), 40 weeks (TRANSCEND-T2D-1), 48 weeks (phase 2), 68 to 80 weeks (TRIUMPH-1, -2, -3, -4 and TRANSCEND-T2D-2) and 104 weeks in the TRIUMPH-1 extension. TRIUMPH-9 is registered at 113 weeks to test different escalation schemes.[21] Doses were adjusted too: the TRIUMPH-1 extension escalated to the maximum tolerated 9 or 12 mg,[14] and in phase 2, 8 participants had protocol-driven dose reductions when BMI fell.[1] TRIUMPH-6 uses an 80-week lead-in on one dose and then 36 weeks randomized to dose 1, dose 2 or placebo, a maintenance design whose results are not out.[21]
No trial reviewed used cycles or planned breaks. The 8-weeks-on, 8-weeks-off pattern seen online has no trial counterpart.
Combinations and stacks
Formally studied
No combination of retatrutide with another peptide has been tested in people, as far as located. Registered interaction studies test retatrutide with midazolam, warfarin, caffeine, metoprolol and an oral contraceptive; results were not read.[24] TRIUMPH-5 compares it against tirzepatide instead of combining them.[21]
Mechanistically plausible
A 2026 rat study found added weight loss when cagrilintide was given with retatrutide. It is animal work and says nothing about human amounts.[25]
Practitioner and community reported
No practitioner stack was located. Education pages list stacks with cagrilintide, MOTS-c, BPC-157, CJC-1295 (no DAC) with ipamorelin, tesamorelin, GHK-Cu, DSIP and AOD-9604. Those pages themselves say no human combination trial exists, and only one gives an amount (BPC-157 250 to 500 mcg a day, no source).[44][50] Popularity is not evidence of safety or benefit.
Side effects, quality and sourcing risks
Trial side effects are listed above: stomach and gut effects that rise with dose and with a fast start, dysesthesia, lower blood pressure, and a heart rate rise that peaked at 24 weeks in phase 2.[1][7] In TRIUMPH-2, deaths were 2, 3 and 1 on retatrutide versus 1 on placebo, all judged unrelated to treatment.[7] Long-term effects beyond 104 weeks are not known.
The bigger variable for people using unapproved vials is what is in the vial. The facts on record:
- The FDA states that retatrutide cannot be used in compounding under federal law, that it has warned telehealth firms, ingredient distributors and outsourcing facilities, and that products are falsely labeled “for research purposes” or “not for human consumption” while sold with dosing instructions, with unknown quality.[28] An FDA letter of 31 March 2025 says compounded retatrutide does not qualify under sections 503A or 503B.[29]
- On 12 August 2026 Lilly announced six lawsuits, one in California and five in Texas, against compounding pharmacies, medical spas and online sellers, alleging “research use only” mislabeling. Lilly says it reported more than 200 entities and more than 14,000 listings.[30][31]
- Public Citizen counted 14 FDA warning letters since December 2024, one person charged in February 2026 and, in the FDA’s adverse event database, 10 reports in 2025 and 26 from January to May 2026, with 11 hospitalizations.[32]
- Testing: an independent testing service reported 2,759 samples in the Public Citizen analysis, with 71 of 179 vendors (39.6%) rated poor, bad or fraud.[32] Its public page now shows 4,650 tests, and 65 of the 200 results visible there failed.[34] An Australian laboratory tested 18 counterfeit samples: one matched its label, about 30% were higher than labeled, about 30% lower, one contained none, and the peptide was usually about 10% of vial contents.[33] Australia’s regulator found semaglutide and no retatrutide in one product (secondary report).[35]
So a label of “10 mg” is a claim, not a measurement. Guides to reading a certificate of analysis explain what a test report does and does not show.
Regulatory and development status
Checked on 2 November 2026 against Lilly’s latest release, the FDA’s GLP-1 page and ClinicalTrials.gov: retatrutide is not approved by the FDA or any other regulator.[16][28] Lilly said on 23 July 2026 that it plans to file a biologics license application with the FDA in the first quarter of 2027 and is completing the manufacturing section.[15] A typical FDA review runs up to about a year,[36] so if the plan holds, a decision would fall in late 2027 to early 2028. That is arithmetic and not a Lilly forecast. Lilly offers pre-approval expanded access to adults with BMI 35 or higher and at least two serious complications.[23] Lilly’s trademark names for the drug are covered in our Retzoundi and Retkouro write-up. For the wider federal discussion of compounded peptides, see our HHS peptide policy summary. The Atlas keeps a retatrutide status page alongside the other obesity drugs.
What is not public
- Single-ascending-dose levels in the phase 1 study, the Chinese and Japanese multiple-dose amounts, and the step sizes of the phase 2 escalation. The phase 2 paper text says only “every 4 weeks for up to 12 weeks”.
- Milligram arms for TRIUMPH-5, -6, -9 and the other registered phase 3 and 3b trials.
- Any weight-adjusted analysis. Mean baseline weights ran from 96.9 kg in TRANSCEND-T2D-1 to 112.7 kg in TRIUMPH-1 (119.6 kg in TRIUMPH-1-OSA), and none of the published papers reviewed reports effects per kilogram.
- Results of the interaction studies and of the first head-to-head against tirzepatide (TRIUMPH-5, primary completion registered as November 2026).[21]
- Any original source for the 0.5 mg start, the 6-to-8-week step interval, the 8-on-8-off cycle or the 10 mg weekly amount seen online.

Retatrutide dosage FAQ
What is the retatrutide dosage?
There is no approved retatrutide dosage because no regulator has approved the drug. In Lilly’s phase 3 trials, adults injected it under the skin once a week, starting at 2 mg and stepping up every 4 weeks to a target of 4, 9 or 12 mg. Phase 2 tested 1, 4, 8 and 12 mg for 48 weeks. [1][14][15]
Is there a retatrutide dosage chart?
The first table on this page is a sourced chart of every amount tested or reported, and the escalation table under the timing section shows the phase 3 ladder: 2 mg, then 4, 6, 9 and 12 mg, one step every 4 weeks. Charts on other sites that show other ladders are mostly community schedules with no trial source. [10][14]
How much retatrutide per week?
In trials, the weekly maintenance amounts were 1, 4, 8, 9 and 12 mg depending on the trial, always as fixed milligram doses. 12 mg a week is the highest maintenance amount in the phase 2 and 3 trials reviewed. Community pages describe 1 to 5 mg a week as common, with no traceable source. [1][6][38]
What is the retatrutide starting dose?
Every phase 3 trial started at 2 mg a week for 4 weeks. Starting at 4 mg instead of 2 mg roughly doubled nausea in phase 2 (36% versus 18% in the 4 mg arm). Online starts of 0.5 to 1 mg are common, but no source for them was found, and no trial used a 0.5 mg start. [1][2][14]
Retatrutide 10 mg vial: how many weeks does it last?
Divide the labeled amount by the weekly amount. A 10 mg vial covers 10 weeks at 1 mg a week, 5 weeks at 2 mg, 2.5 weeks at 4 mg and under 1 week at 12 mg. This assumes the label is accurate, and independent testing of unapproved vials has found wrong amounts and counterfeits. [32][33]
How long are retatrutide cycles?
The trials had no cycles. Participants dosed continuously for 12 weeks (phase 1b), 40 to 80 weeks (most phase 3 trials) and up to 104 weeks in the TRIUMPH-1 extension. Cycles of 8 weeks on and 8 off, 12 or 24 weeks, or 48 weeks appear on community and education pages without a source. [3][14][44]
Is retatrutide dosed by weight?
Not in any trial reviewed. Every trial used fixed milligram doses, not milligrams per kilogram, even though baseline weights ran from about 97 to 113 kg. No published weight-adjusted analysis was found, so a per-kilogram figure would be an assumption. [6][8]
Retatrutide vs tirzepatide: how do the doses and results compare?
Tirzepatide is approved at 5, 10 and 15 mg weekly for weight loss. In SURMOUNT-1 it produced weight changes of -15.0%, -19.5% and -20.9% at 72 weeks (treatment-regimen), against -17.6%, -23.7% and -25.0% for retatrutide 4, 9 and 12 mg at 80 weeks in TRIUMPH-1. These are separate trials. TRIUMPH-5 is the planned head-to-head. [6][21][27]
Is retatrutide legal?
Retatrutide is not approved, so it is not legal to market as a medicine. The FDA says it cannot be used in compounding under federal law and warns that products sold as for research are falsely labeled and of unknown quality. Lilly has sued sellers, and warning letters have been issued. This page makes no claim about any individual’s legal position. [28][29][30]
When will retatrutide be approved?
No date has been given. Lilly plans to file with the FDA in the first quarter of 2027. A typical FDA review runs up to about a year, so a decision would come in late 2027 to early 2028 if the plan holds. That is arithmetic from the filing plan, not a Lilly forecast. [15][36]
Bottom line
Retatrutide has no approved dose, but it has a lot of trial data: weekly injections stepped up every 4 weeks from 2 mg to 4, 9 or 12 mg, with weight loss of roughly 17% to 25% at 80 weeks in people without diabetes under the conservative estimand. The published evidence supports the shape of the dose response, not a personal amount. What circulates online is mostly lower starts, slower steps and cycles that no trial used, and the sources behind those figures could not be traced. Meanwhile the vials themselves are the weakest link, with independent testing finding wrong amounts and fake contents. Lilly expects to file in early 2027.
Keep reading
Sources
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. N Engl J Med. 2023;389(6):514-526. Published 26 June 2023. https://doi.org/10.1056/NEJMoa2301972 Published human clinical trial (Tier 1). Funded by Eli Lilly. PMID 37366315. Arm-level detail read from the full text.
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. Published 26 June 2023. https://doi.org/10.1016/S0140-6736(23)01053-X Published human clinical trial (Tier 1). Funded by Eli Lilly. PMID 37385280.
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. Published 27 October 2022. https://doi.org/10.1016/S0140-6736(22)02033-5 Published human clinical trial (Tier 1). Funded by Eli Lilly. PMID 36354040.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. Published 18 August 2022. https://doi.org/10.1016/j.cmet.2022.07.013 Published animal research (Tier 3) plus phase 1 single ascending dose data (Tier 1). PMID 35985340.
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. Published 10 June 2024. https://doi.org/10.1038/s41591-024-03018-2 Published human clinical trial (Tier 1). Substudy of the phase 2 obesity trial. PMID 38858523.
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. Published 29 September 2026. https://doi.org/10.1056/NEJMoa2604169 Published human clinical trial (Tier 1). Funded by Eli Lilly. PMID 42814954. Abstract read.
- Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. Published 29 September 2026. https://doi.org/10.1016/S0140-6736(26)01861-1 Published human clinical trial (Tier 1). Funded by Eli Lilly. PMID 42810372.
- Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1). Lancet. 2026;407(10546):2402-2413. Published 6 June 2026. https://doi.org/10.1016/S0140-6736(26)00967-0 Published human clinical trial (Tier 1). Funded by Eli Lilly. PMID 42250575.
- Grunstein RR, Somers VK, Azarbarzin A, et al. Retatrutide once weekly for treatment of obstructive sleep apnea (TRIUMPH-1-OSA and TRIUMPH-2-OSA). N Engl J Med. Published 21 October 2026. https://doi.org/10.1056/NEJMoa2611477 Published human clinical trial (Tier 1). Funded by Eli Lilly. PMID 42904878.
- Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93. Published 15 October 2025. https://doi.org/10.1111/dom.70209 Trial design paper by sponsor authors (Tier 2 context). PMID 41090431.
- Heerspink HJL, van Raalte DH, Bjornstad P, et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026;41(6):1058-1068. https://doi.org/10.1093/ndt/gfaf230 Design and baseline paper; no efficacy results (Tier 2 context). PMID 41160422.
- Eli Lilly and Company. Lilly’s triple agonist retatrutide demonstrated significant reductions in A1C and weight in first phase 3 trial for treatment of type 2 diabetes (TRANSCEND-T2D-1). Press release, 19 March 2026. https://lilly.gcs-web.com/node/54026 Company announcement, sponsor-reported, not peer reviewed.
- Eli Lilly and Company. Lilly’s triple agonist retatrutide delivered weight loss of up to an average of 71.2 lbs and relief from osteoarthritis pain in the first successful phase 3 trial (TRIUMPH-4). Press release, 11 December 2025. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average Company announcement, sponsor-reported, not peer reviewed.
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal phase 3 obesity trial (TRIUMPH-1). Press release, 21 May 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss Company announcement, sponsor-reported, not peer reviewed.
- Eli Lilly and Company. Lilly’s triple agonist retatrutide successful in two additional phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3). Press release, 23 July 2026. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional Company announcement, sponsor-reported, not peer reviewed. Source of the Q1 2027 filing statement.
- Eli Lilly and Company. Lilly’s retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic’s highest approved dose in head-to-head trial (TRANSCEND-T2D-2). Press release, 28 October 2026. https://investor.lilly.com/node/55186 Company announcement, sponsor-reported, not peer reviewed.
- ClinicalTrials.gov. Phase 1 records: NCT03841630 (single ascending dose, healthy participants), NCT04143802 (multiple ascending dose, type 2 diabetes), NCT05548231 (Chinese participants), NCT04823208 (Japanese participants with type 2 diabetes). Sponsor: Eli Lilly and Company. https://clinicaltrials.gov/study/NCT04143802 Trial registry records (Tier 2). Dose levels for the single ascending dose, Chinese and Japanese studies were not stated in the summaries read.
- ClinicalTrials.gov. Phase 2 records: NCT04881760 (obesity), NCT04867785 (type 2 diabetes), NCT05936151 (TRANSCEND-CKD, chronic kidney disease). Sponsor: Eli Lilly and Company. https://clinicaltrials.gov/study/NCT04881760 Trial registry records (Tier 2). Results for the first two are in references 1 and 2.
- ClinicalTrials.gov. TRIUMPH phase 3 records: NCT05929066 (TRIUMPH-1), NCT05929079 (TRIUMPH-2), NCT05882045 (TRIUMPH-3), NCT05931367 (TRIUMPH-4). Sponsor: Eli Lilly and Company. https://clinicaltrials.gov/study/NCT05929066 Trial registry records (Tier 2). All four listed as completed.
- ClinicalTrials.gov. TRANSCEND phase 3 records: NCT06354660 (TRANSCEND-T2D-1), NCT06260722 (TRANSCEND-T2D-2), NCT06297603 (type 2 diabetes with renal impairment on basal insulin). Sponsor: Eli Lilly and Company. https://clinicaltrials.gov/study/NCT06260722 Trial registry records (Tier 2).
- ClinicalTrials.gov. Other registered retatrutide phase 3 and 3b records: NCT06662383 (TRIUMPH-5, versus tirzepatide), NCT06859268 (TRIUMPH-6, maintenance), NCT07357415 (TRIUMPH-9, dose escalation schemes), NCT07232719, NCT07035093 (chronic low back pain), NCT06383390 (cardiovascular and kidney outcomes), NCT07165028 (liver disease master protocol). Sponsor: Eli Lilly and Company. https://clinicaltrials.gov/study/NCT07357415 Trial registry records (Tier 2). No results posted; milligram arms are not stated in the summaries read.
- ClinicalTrials.gov. NCT07467447: a phase 2 study of once-weekly LY3437943 (retatrutide) compared with placebo in participants with obesity or overweight. Sponsor: Hudson Biotech. https://clinicaltrials.gov/study/NCT07467447 Trial registry record (Tier 2). Recruiting; one site in Shenzhen, China. The record does not state any connection to Lilly.
- ClinicalTrials.gov. NCT07629401: Pre-approval expanded access of retatrutide (LY3437943). Sponsor: Eli Lilly and Company. https://clinicaltrials.gov/study/NCT07629401 Expanded access registry record. Status: available.
- ClinicalTrials.gov. Interaction and pharmacokinetic studies: NCT05445232 (midazolam, warfarin, caffeine), NCT06808802 (metoprolol), NCT06039826 (ethinyl estradiol and drospirenone), NCT06003465 (device formulation). Sponsor: Eli Lilly and Company. https://clinicaltrials.gov/study/NCT06808802 Trial registry records (Tier 2). Completed; results not read.
- Petersen J, Merrild C, Holm SK, et al. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nat Metab. 2026;8(10):2069-2083. Published 15 September 2026. https://doi.org/10.1038/s42255-026-01603-y Published animal research (Tier 3). PMID 42744908. Doses are not in the abstract.
- Mateescu DM, Capraru ID, Enache B, et al. Retatrutide as a unimolecular GIP/GLP-1/glucagon receptor tri-agonist: molecular design, pharmaceutical development and critical interpretation of emerging phase 3 evidence. Pharmaceutics. 2026;18(10):1277. Published 9 October 2026. https://doi.org/10.3390/pharmaceutics18101277 Narrative review (expert commentary). PMID 42942810.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://doi.org/10.1056/NEJMoa2206038 Published human clinical trial (Tier 1). Comparator context only. PMID 35658024.
- U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of 1 October 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Regulator statement.
- Ohio Board of Pharmacy. Retatrutide: FDA letter to the National Association of Boards of Pharmacy dated 31 March 2025 and NABP memo of 3 April 2025. https://www.pharmacy.ohio.gov/reta State regulator page reproducing an FDA letter.
- Healio. Eli Lilly files lawsuits against six companies for allegedly selling retatrutide. 14 August 2026. https://www.healio.com/news/endocrinology/20260814/eli-lilly-files-lawsuits-against-six-companies-for-allegedly-selling-retatrutide Trade press report.
- Fierce Pharma. Lilly takes 6 companies to court for selling retatrutide knockoffs. August 2026. https://www.fiercepharma.com/pharma/lilly-takes-6-companies-court-selling-retatrutide-knockoffs Trade press report.
- Whoriskey P. The “miracle drug” and the peptide craze: the HHS chief touts peptides as the agency looks the other way on retatrutide. Public Citizen Health Research Group, 16 June 2026. https://www.citizen.org/wp-content/uploads/Retatrutide-Report.pdf Advocacy group report. Secondary source for testing and adverse event counts.
- Carbonell R, Gribbin C, Yu A. New testing of black market peptides reveals dangerous dosing levels. ABC News (Australia), 28 August 2026. https://www.abc.net.au/news/2026-08-28/black-market-peptides-dangerous-doses/107059092 News report of independent laboratory testing.
- Finnrick. Retatrutide: independent test results and vendor ratings. Public page read 2 November 2026. https://www.finnrick.com/products/retatrutide Independent testing service, public aggregate page.
- Healthline. Retatrutide: risks of using before FDA approval. Written 21 October 2026, medically reviewed by Andrew Perugini, PharmD. https://www.healthline.com/health/drugs/retatrutide Consumer health publisher.
- Drugs.com. Retatrutide: uses, status and FDA filing plans. https://www.drugs.com/retatrutide.html Drug information publisher; secondary source for status.
- Lilly Medical Information. What is retatrutide? Date of last review 18 March 2024. https://medical.lilly.com/us/products/answers/what-is-retatrutide-233361 Sponsor medical information page.
- EliteFitness forum. “How much RETA do you recommend?” Thread started 18 July 2026, 12 posts. https://www.elitefitness.com/forum/threads/how-much-reta-do-you-recommend.1518104/ Community forum thread (Tier 6). Anecdotal.
- Evolutionary.org forums. “Retatrutide and running it at 4 mg, side effects.” Thread started 28 June 2026, 16 posts. https://www.evolutionary.org/forums/threads/retatrutide-and-running-it-at-4-mg-side-effects.111955/ Community forum thread (Tier 6). Anecdotal.
- RADAR Writes (Substack). “Retatrutide update.” 27 November 2025. https://radarwritesfiction.substack.com/p/retatrutide-update Personal blog account (Tier 6). Anecdotal.
- Peptidepedia. Retatrutide dosage. https://peptidepedia.org/weight-loss/retatrutide/dosage Peptide education website (Tier 6). Dosing figures cite no sources.
- Peptide Protocol Wiki. Retatrutide: dosing protocols. https://www.peptideprotocolwiki.com/peptides/retatrutide/dosing Peptide education website (Tier 6). Escalation table cites no source.
- Peptide Dosing Protocols. Retatrutide protocol guide: dosing, reconstitution and safety. https://www.peptidedosingprotocols.com/protocol/retatrutide Peptide education website (Tier 6). Cites Giblin 2025 and Lilly releases for trial schedules; vial and reconstitution examples cite no source.
- The Peptide Catalog. Retatrutide dosage chart: doses, units and titration. https://thepeptidecatalog.com/articles/retatrutide-dosing-guide Peptide education or catalog website (Tier 6). Community figures cite no source.
- PeptideDosage.org. Retatrutide dosage chart, schedule and reconstitution protocol. https://www.peptidedosage.org/peptides/retatrutide/dosage Peptide education website (Tier 6). Reference list contains mismatched identifiers.
- GLP3 Planner. Retatrutide titration schedule 2026. https://glp3planner.com/resources/retatrutide-titration-schedule Affiliate-linked planner site (Tier 6). Discloses vendor affiliate links.
- GLP3 Planner. Retatrutide Reddit: what real users report in 2026. Threads captured 26 May 2026. https://glp3planner.com/resources/retatrutide-reddit-roundup Secondary roundup of Reddit posts (Tier 6). The Reddit threads themselves were not read.
- Middleway Nutrition. Retatrutide dosage chart: week-by-week guide. https://www.middlewaynutrition.com/glp-1/retatrutide-dosage-chart Commercial affiliate page (Tier 6). Community ramp has no cited source.
- IAPAM. Retatrutide dosage: a guide. Page dated September 2026. https://iapam.com/medical-weight-management-library/retatrutide-dosage-a-guide Clinic education page (Tier 5 to 6). States no community dose is published.
- Peptide Protocol Wiki. Best peptides to stack with retatrutide, 2026; and Peptide Dosing Protocols. Retatrutide stack options. https://www.peptideprotocolwiki.com/blog/best-peptides-to-stack-with-retatrutide-2026 https://www.peptidedosingprotocols.com/blog/retatrutide-stack-options Peptide education websites (Tier 6). Both state no combination has been studied in humans and give no amounts.
PeptideBlog.net is an educational reference. It documents published research and information circulating online, does not give medical advice, and does not recommend any amount, product or source. Evidence tiers follow our evidence standards.